Agenus (NASDAQ:AGEN - Get Free Report) issued its quarterly earnings results on Monday. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.61) by $0.58, Zacks reports. The company had revenue of $24.07 million during the quarter, compared to analyst estimates of $26.38 million.
Agenus Stock Performance
NASDAQ:AGEN traded down $0.09 during trading hours on Thursday, hitting $3.38. The stock had a trading volume of 682,985 shares, compared to its average volume of 586,907. The business's 50 day moving average is $2.19 and its 200-day moving average is $2.92. Agenus has a one year low of $1.38 and a one year high of $19.69. The company has a market cap of $71.56 million, a price-to-earnings ratio of -0.30 and a beta of 1.48.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on AGEN shares. Robert W. Baird increased their target price on Agenus from $3.00 to $4.00 and gave the stock a "neutral" rating in a research report on Tuesday. B. Riley restated a "buy" rating on shares of Agenus in a research note on Monday, April 21st. StockNews.com upgraded shares of Agenus from a "sell" rating to a "hold" rating in a report on Friday, March 21st. Finally, HC Wainwright reiterated a "neutral" rating on shares of Agenus in a report on Tuesday. Six research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat, Agenus currently has an average rating of "Hold" and a consensus target price of $9.00.
Get Our Latest Research Report on AGEN
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Agenus stock. Invesco Ltd. purchased a new position in shares of Agenus Inc. (NASDAQ:AGEN - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 58,281 shares of the biotechnology company's stock, valued at approximately $88,000. Invesco Ltd. owned about 0.28% of Agenus at the end of the most recent quarter. Hedge funds and other institutional investors own 61.46% of the company's stock.
About Agenus
(
Get Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Featured Articles
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
